While vaccination programmes continue to scale up around the world, therapeutics play a key role in saving lives, freeing up capacity in intensive care units and treating patients living with long-COVID.
The pharmaceutical industry is working around the clock to develop new tools to help patients and clinicians fight COVID-19. There are currently nearly 3000 clinical trials exploring therapeutics for treating COVID patients and around 61 therapeutic candidates such as anti-virals, monoclonal antibodies, anti-hypertensives, anti-inflammatories, immunomodulators, anti-thrombotics and steroids in the latter stages of development.
The European Commission's COVID-19 Therapeutics Strategy aims to accelerate the continued development, delivery and availability of therapeutics for use in the fight against COVID-19 in Europe and around the world.Join us on 29 June 2021 to learn more about the importance of therapeutics in mitigating the impact of COVID-19 on people, on health systems and on society
- Jenny Camaradou, EUPATI Fellow Patient Expert, Innovation R&D consultant and COVID-END Horizon scanning Global Panel Member
- Pierre Delsaux, Deputy Director General, DG for Health and Food Safety, European Commission
- Massimiliano Di Domenico, VP Communications, Government Affairs and Market Access Europe, GlaxoSmithKline (GSK)
- Michel Goldman, President of the Institute for Interdisciplinary Innovation in healthcare (Université Libre de Bruxelles, Belgium) and former IMI Executive Director
- Nathalie Moll, Director General of EFPIA